What is URGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.69B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for URGN?

P/E (TTM) is n/a and 52-week range is $16.50 to $50.81 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s URGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for URGN?

The company profile lists revenue (TTM) near $183M, net income (TTM) near -$9.47B, EPS (TTM) near -$1.98 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Urogen Pharma Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ra'anana, IL, 48.9M shares outstanding, ISIN IL0011407140 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Urogen Pharma Ltd

$URGN

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Employees

298

Website

www.urogen.com/

IPO

2017-05-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)